Mobile website
Archive > Volume 26 Issue 7 > 2019,26(7):788-792. DOI:10.3872/j.issn.1007-385X.2019.07.011 Prev Next
Clinical Research
Association of SCN10A single nucleotide polymorphism rs12632942 and oxaliplatin-induced peripheral neuropathy in colorectal cancer patients receiving chemotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Objective: To explore the association between single nucleotide polymorphism rs12632942 in SCN10A exon and oxaliplatin-induced peripheral neuropathy (OXLIPN) in colorectal cancer (CRC) patients receiving chemotherapy. Methods:A total of 319 cases of blood samples from CRC patients receiving chemotherapy regimen with Oxaliplatin (OXL) were collected from the Second Affiliated Hospital of Guangzhou Medical University, the Second Affiliated Hospital of Nanchang University, and Guangzhou Baiyun District Hospital of Chinese Medicine during January 2011 and June 2013. DNA was routinely extracted, and PCR amplification was performed to analyze the genotype of rs12632942; and OXLIPN of patients was also evaluated. The association between rs12632942 genotype and OXLIPN was analyzed by χ2 test and multivariate logistic regression model. Results: The genotypes of rs12632942 of 319 CRC patients:AA of 134 cases, AG of 156 cases and GG of 29 cases; and the genotype distribution of rs12632942 was in accordance with Har-dy-Weinberg equiliberum (P>0.05). χ 2 test showed that rs12632942AG+GG genotype was associated with Ⅱ-Ⅳ degree OXLIPN (P<0.01). Multivariate logistic regression model showed that rs12632942 AG + GG genotype was an independent risk factor for Ⅱ-Ⅳ degree OXLIPN（OR=2.044；95%CI=1.231-3.392; P<0.01）. Conclusion: Colorectal cancer patients with SCN10A exon polymorphism rs12632942 AG + GG genotype were susceptible to Ⅱ-Ⅳ degree OXLIPN.
Keywords:
Project Supported:
Project supported by the Science and Technology Program of Guangzhou City (No.201804010072), the Public Welfare Research and Capacity Building Special Fund of Guangdong Province (No.2014A020212333), and the Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation of Guangdong Province (No.2017B030314026)
Clc Number:
